EGFR and non-small cell lung carcinoma: Importantly, tryptophan was only the metabolite that consistently differed across all group comparisons: healthy controls vs. NSCLC patients, EGFR-mutant vs. wild-type NSCLC, and treatment-naïve vs. TKI-resistant EGFR-mutant NSCLC.